LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

3.49 18.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.95

Максимум

3.82

Ключови измерители
By Trading Economics
Приходи	-31M -14M
Продажби	-32M 41M
EPS	-0.22
Марж на печалбата	-34.333
Служители	293
EBITDA	-37M -15M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+79.83% upside

Дивиденти
By Dow Jones
Следващи печалби	19.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	65M 188M
Предишно отваряне	-14.82
Предишно затваряне	3.49

Настроения в новините

By Acuity

23%

77%

51 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.05.2026 г., 22:50 ч. UTC

Печалби

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12.05.2026 г., 22:49 ч. UTC

Печалби

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12.05.2026 г., 22:32 ч. UTC

Печалби

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Печалби

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12.05.2026 г., 22:26 ч. UTC

Печалби

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure Interim Dividend A$0.50/Security

12.05.2026 г., 22:24 ч. UTC

Печалби

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12.05.2026 г., 22:19 ч. UTC

Печалби

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA: Business Lending Continued to Grow Above System>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12.05.2026 г., 22:13 ч. UTC

Печалби

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12.05.2026 г., 22:11 ч. UTC

Печалби

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12.05.2026 г., 22:11 ч. UTC

Печалби

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12.05.2026 г., 22:10 ч. UTC

Печалби

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12.05.2026 г., 22:08 ч. UTC

Печалби

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12.05.2026 г., 22:07 ч. UTC

Печалби

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12.05.2026 г., 22:05 ч. UTC

Печалби

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

79.83% нагоре

12-месечна прогноза

Среден 6.33 USD 79.83%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

51 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.